CEO and Chairman
Dr. Frost has been the CEO and Chairman of OPKO since March 2007. Previously, Dr. Frost served at Teva Pharmaceutical Industries, Limited ("Teva") as both Chairman of the Board and Vice Chairman. Dr. Frost served as Chairman of the Board of Directors and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He also served as chairman for Key Pharmaceuticals, Ladenburg Thalmann Financial Services and was a director of Continucare Corporation and Castle Brands, Inc. He was also a Governor and Co-Vice-Chairman of the American Stock Exchange.
Dr. Frost is a past chairman and currently serves as a member of the Board of Trustees of the University of Miami, the Shanghai Institute for Advanced Immunochemical Studies in China, and as a Trustee of the Miami Jewish ÄÐÈË¹¬µî for the Aged and the Mount Sinai Medical Center. He also serves as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He is a past member of the Board of Trustees of the Scripps Research Institute, the Board of Regents of The Smithsonian Institution, and the Skolkovo Foundation Scientific Advisory Council in Russia.
Dr. Frost is a director of Cocrystal Pharma, Inc., a publicly traded biotechnology company developing new treatments for viral diseases.
Alexis Borisy is a leading biotechnology entrepreneur and investor with more than 25 years of experience, including founding, being the CEO, and/or Chairman of 9 NASDAQ listed companies. He co-founded and served as either the CEO or Chairman of Blueprint Medicines, Foundation Medicine, Relay Therapeutics, Tango Therapeutics, Celsius Therapeutics, and CombinatoRx. Heâ€™s also a founding investor for Editas Medicine, Magenta Therapeutics, Revolution Medicines and Thrive Earlier Detection. Alexis is the Chairman of the Board of Trustees of the Boston Museum of Science, and is past Chairman of the National Venture Capital Association. He holds a masterâ€™s degree in chemistry and chemical biology from Harvard University and a B.S. in chemistry from the University of Chicago.
CTO and Vice Chairman
Dr. Hsiao has served as Vice-Chairman and Chief Technical Officer at OPKO since May 2007 and as a director since February 2007. Previously, Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical, and Neovasc, Inc.
Dr. Hsiao has served since 2008 as Chairman of the Board of Non-Invasive Monitoring Systems, Inc., a medical device company and was named Interim CEO of the company in 2012. Dr. Hsiao is also a director of TransEnterix, Inc., a medical device company, and Cocrystal Pharma, Inc.
Richard M. Krasno, Ph.D.
Dr. Krasno was appointed to the OPKO Board in 2017. Previously, Dr. Krasno served as executive director of the William R. Kenan, Jr. Charitable Trust and as President of the four affiliated William R. Kenan, Jr. Funds.
Prior to joining the Trust, Dr. Krasno was the President of the Monterey Institute of International Studies in Monterey, California. Dr. Krasno also served as a director of the University of North Carolina Health Care System and as chairman of the board of directors until 2012. He has also served as President and Chief Executive Officer of the Institute of International Education in New York, and as Deputy Assistant Secretary of Education in Washington, D.C.
Dr. Krasno currently serves as a director of Ladenburg Thalmann and BioCardia, Inc. and previously served as a director of Castle Brands, Inc. Dr. Krasno holds a Bachelor of Science from the University of Illinois and a Ph.D. from Stanford University.
Prem A. Lachman, M.D
Dr. Lachman is a healthcare investment manager with more than 35 years of experience in portfolio management, biopharmaceutical investment research and healthcare investment banking. Additionally, Dr. Lachman is supported by a foundation in medicine and gastroenterology research. Dr. Lachman founded Maximus Capital, LLC in 2001 and currently serves as its general partner. Dr. Lachman previously served as the general partner of The Galleon Group from 1998 to 2001 and as Managing Director, Investment Research at Goldman Sachs & Co. from 1989 to 1998. Dr. Lachman is a Directors Council board member of the Museum of Modern Art, a patron of the Metropolitan Opera, and a board member of the Department of Surgery at Mount Sinai Medical Center in New York.
Roger J. Medel, M.D.
Dr. Medel is the co-founder of MEDNAX, Inc., a national health solutions partner comprised of the nationâ€™s leading providers of physician services, and has served as a director of MEDNAX since 1979. Dr. Medel served as MEDNAXâ€™s President until May 2000 and again from March 2003 until May 2004. He served as Chief Executive Officer of MEDNAX from 1979 until December 2002, and again from March 2003 until July 2020 when he retired. Dr. Medel has served as a member of the Board of Trustees of the Dana Farber Cancer Institute, Inc. since January 2016. He was a member of the Board of Trustees of the University of Miami from January 2004 to February 2012. Dr. Medel actively participates as a member of several medical and professional organizations and from June 2006 to April 2009, served on the Board of Directors of MBF Healthcare Acquisition Corp.
Gary J. Nabel
Chief Innovation Officer and Director
Dr. Gary J. Nabel M.D., Ph.D. has been the President and CEO of ModeX Therapeutics Inc., a start-up biotechnology company focused on multispecific immune therapies for cancer and viral diseases, since November 2020. He previously worked as Chief Scientific Officer and Senior Vice President of Sanofi from 2012-2020. A virologist and immunologist, Dr. Nabel served as founding director of NIHâ€™s Vaccine Research Center (VRC) and its leader for 14 years (1999-2012) working on vaccines and broadly neutralizing antibodies against HIV, influenza, SARS, Ebola, Chikungunya and Epstein-Barr virus. He was previously an investigator at the Howard Hughes Medical Institute at the University of Michigan (1987-1999). In recognition of his expertise at the forefront of virology, immunology, gene therapy, and molecular biology, Dr. Nabel was elected to the National Academy of Medicine and is a fellow of the American Association of Physicians, the American Academy of Arts Sciences, and the Geoffrey Beene Builders of Science Award from Research America. He worked previously as the board chair for the non-profit Keystone Symposia and currently serves on the board of Siga Technologies Inc., a publicly traded biotechnology company.
John A. Paganelli
Mr. Paganelli has served as a director of OPKO since December 2003. Previously, Mr. Paganelli served as OPKO's Interim CEO and secretary, and Chairman of OPKO's Board of Directors until 2007. Mr. Paganelli also served as President and CEO of Transamerica Life Insurance Company of New York.
Since 1987, Mr. Paganelli has been a partner in RFG Associates, a financial planning organization. Mr. Paganelli is also the Managing Partner of Pharos Systems Partners, LLC, an investment company, and served as Chairman of the Board of Pharos Systems International, a software company, from 2001 until March 2021. He was Vice President and Executive Vice President of PEG Capital Management, an investment advisory organization. Mr. Paganelli was also an officer and director-stockholder of Mike Barnard Chevrolet, Inc., an automobile dealership. Mr. Paganelli also serves as a director of Western New York Energy, LLC. Mr. Paganelli previously served on the Board of Trustees of Paul Smith's College and the Board of Managers of Bridge Financial Services, LLC.
Richard C. Pfenniger, Jr.
Mr. Pfenniger has served as a director of OPKO since January 2008. Mr. Pfenniger served as CEO and President for Continucare Corporation, a provider of primary care physician and practice management services, and as Chairman of the Board of Directors of Continucare Corporation until 2011. Mr. Pfenniger has also served as the CEO and Vice Chairman of Whitman Education Group, Inc.
Prior to joining Whitman, he served as the Chief Operating Officer of IVAX and as the Senior Vice President-Legal Affairs and General Counsel of IVAX. Mr. Pfenniger currently serves as a director of GP Strategies Corporation, a corporate education and training company, TransEnterix Inc., a medical device company pioneering the use of robotics, IntegraMed America, and BioCardia, Inc., a clinical-stage regenerative medicine company. He also serves as the Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science.
Executive Vice President, Administration
Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a director since February 2007. Previously, Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006.
Mr. Rubin currently serves on the board of directors of Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates; Non-Invasive Monitoring Systems, Inc., a medical device company; Cocrystal Pharma, Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses; ChromaDex Corp., a science-based integrated nutraceutical company devoted to improving the way people age; Neovasc, Inc. a company developing and marketing medical specialty vascular devices, and Red Violet, Inc., leading analytics and information solutions provider.
Mr. Rubin previously served as a director of Castle Brands, Inc., Dreams, Inc., Safestitch Medical, Inc., Cogent, Inc., PROLOR Biotech, Inc., BioCardia, Inc., and VBI Vaccines, Inc.
Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Yu has been a Director since 2009. Previously, she served as Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. Since 2013, she has been a Distinguished Chair Professor at Chang Gung Memorial Hospital at Linkou, and Chang Gung University in Taiwan.
Dr. Yu has also served as a Professor of Pediatrics for both the National Taiwan University and the University of California in San Diego, where she was the Chief of Pediatric Hematology Oncology. Dr. Yu has also served in several government-appointed positions and is a member of numerous scientific committees and associations.
Elias A. Zerhouni M.D.
President of ÄÐÈË¹¬µî and Vice Chairman
Dr. Elias A. Zerhouni M.D. has been the chairman and co-founder of ModeX therapeutics Inc., a start-up biotechnology company focused on multi specific-immune therapies for cancer and viral diseases, since November 2020. A physician scientist in Imaging and Biomedical Engineering, he served as President of global R&D and executive Vice President of Sanofi form 2010-2018, as Senior Fellow for global health research at the Bill and Melinda Gates foundation 2009-2010 and Presidential US envoy for science and technology 2009-2010. He was director of the US national Institutes of Health 2002-2008, Executive Vice Dean and Dean for research at the Johns Hopkins School of medicine 1996-2002, Professor of Radiology and Biomedical Engineering and chair of the department of Radiological sciences. Dr Zerhouni was elected to the National Academy of Medicine and to the National Academy of Engineering. He serves on the Board of the Lasker Foundation, the Foundation for NIH and the board of Research!America. He received the 2017 Scripps Executive of the year Award for the pharmaceutical industry and the French Legion of Honor in 2008. He has been a director of the publicly traded Danaher Corporation since 2009 to the present.